Clinical Trials · NCT04027348

Palliative Management of Inoperable Malignant Bowel Obstruction

TerminatedPhase 2Octreotide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
Roswell Park Cancer Institute
Enrollment
15
Start date
Jun 2019
Locations
1 site, United States
Primary endpoint
Proportion of Patients With Obstruction Clearance
View Octreotide compound reference